Search results
Results from the WOW.Com Content Network
Triamcinolone is a glucocorticoid used to treat certain skin diseases, allergies, and rheumatic disorders among others. [6] It is also used to prevent worsening of asthma and chronic obstructive pulmonary disease (COPD). [6] It can be taken in various ways including by mouth, injection into a muscle, and inhalation. [6]
Triamcinolone acetonide is also used in veterinary medicine as an ingredient in topical ointments and in topical sprays for control of pruritus in dogs. [28] A series of injections with triamcinolone acetonide or another corticosteroid may reduce keloid size and irritation. It is used as a preinductor and/or inductor of birth in cows.
Triamcinolone benetonide (brand names Alcorten, Benecorten, Tibicorten; also known as triamcinolone acetonide 21-(benzoyl-β-aminoisobutyrate) or TBI) is a synthetic glucocorticoid corticosteroid. [ 1 ] [ 2 ] [ 3 ]
Triamcinolone hexacetonide (brand name Aristospan; also known as triamcinolone acetonide 21-tebutate) is a synthetic glucocorticoid corticosteroid. [ 3 ] [ 4 ] [ 5 ] It is on the World Health Organization's List of Essential Medicines .
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
Intralesional corticosteroid (usually triamcinolone) injection has been used for small, localized hemangiomas, where it has been demonstrated to be relatively safe and effective. [ 59 ] [ 60 ] Injection of upper eyelid hemangiomas is controversial, given the reported risk of retinal embolization, possibly related to high injection pressures.
Some recommend using the topical steroid for 3 consecutive days on, followed by 4 consecutive days off. [10] Long-term use of topical steroids can lead to secondary infection with fungus or bacteria (see tinea incognito ), skin atrophy, telangiectasia (prominent blood vessels), skin bruising and fragility.
For many biologics (e.g., monoclonal antibodies), injection site reactions are the most common adverse effect of the drug, and have been reported to have an incidence rate of 0.5–40%. [ 2 ] In trials of subcutaneous administration of oligonucleotides , between 22 and 100% of subjects developed reactions depending on the oligonucleotide.